Saturday 17 October 2026
Export ENLV’s income statement to Excel — free account
Enlivex Ltd.
ENLV Healthcare Biotechnology
In the quarter to June 2026, EPS grew 5,185.1% and free cash flow grew 35.9%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
0.21
0.01
−4.55%
Follow ENLV
Enlivex Ltd. (ENLV) P/E ratio
As of 16 October 2026, Enlivex Ltd. (ENLV) trades at a P/E ratio of 0.0×. Over the past ten years it has ranged from 0.0× (December 2025) to 0.0× (March 2026); the current reading is higher than 93% of that period. That is below the Biotechnology industry median of 8.5× and below the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
93
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| DRMA Dermata Therapeutics, Inc. compare | n/m |
| LIMN Liminatus Pharma Inc. compare | n/m |
| LGVN Longeveron Inc. compare | n/m |
| NCNA NuCana PLC Sponsored ADR compare | n/m |
| ADTX Aditxt, Inc. compare | n/m |
| XBIO Xenetic Biosciences, Inc. compare | n/m |
| ENLV Enlivex Ltd. | 0.0× |
| AZTR Azitra, Inc. compare | 1.0× |
| PCSA Heatwurx Inc. compare | 1.6× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)